SeaStar Medical Holding Gestion

Gestion contrôle des critères 3/4

Le PDG SeaStar Medical Holding est Eric Schlorff, nommé en Jul2019, a un mandat de 5.33 ans. La rémunération annuelle totale est $ 637.96K, composée du salaire de 65.8% et des bonus 34.2%, y compris les actions et options de la société. détient directement 1.12% des actions de la société, d'une valeur de $ 100.21K. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 2.3 ans et 0.9 ans.

Informations clés

Eric Schlorff

Directeur général

US$638.0k

Rémunération totale

Pourcentage du salaire du PDG	65.8%
Durée du mandat du directeur général	5.3yrs
Propriété du PDG	1.1%
Durée moyenne d'occupation des postes de direction	2.3yrs
Durée moyenne du mandat des membres du conseil d'administration	less than a year

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Eric Schlorff a-t-elle évolué par rapport aux bénéfices de SeaStar Medical Holding?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Sep 30 2024	n/a	n/a	-US$30m
Jun 30 2024	n/a	n/a	-US$33m
Mar 31 2024	n/a	n/a	-US$32m
Dec 31 2023	US$638k	US$420k	-US$26m
Sep 30 2023	n/a	n/a	-US$25m
Jun 30 2023	n/a	n/a	-US$20m
Mar 31 2023	n/a	n/a	-US$18m
Dec 31 2022	US$2m	US$320k	-US$12m
Sep 30 2022	n/a	n/a	-US$5m
Jun 30 2022	n/a	n/a	-US$4m
Mar 31 2022	n/a	n/a	-US$5m
Dec 31 2021	US$323k	US$300k	-US$5m

Rémunération vs marché: La rémunération totale de Eric ($USD 637.96K ) est dans la moyenne des entreprises de taille similaire sur le marché US ($USD 649.63K ).

Rémunération et revenus: La rémunération de Eric a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.

PDG

Eric Schlorff (51 yo)

5.3yrs

Titularisation

US$637,960

Compensation

Mr. Eric Schlorff serves as Chief Executive Officer and Executive Director of SeaStar Medical Holding Corporation since July 2019 and serves as its President. He served as Chief Operating Officer at LMF Ac...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Eric Schlorff	CEO, President & Executive Director	5.3yrs	US$637.96k	1.12% $ 100.2k
Kevin Chung	Chief Medical Officer	2.3yrs	US$495.31k	0.31% $ 28.1k
H. Humes	Co-Founder and Managing Director	29.8yrs	US$205.93k	pas de données
David Green	Chief Financial Officer	less than a year	pas de données	0.24% $ 21.2k
Tom Mullen	Vice President of Operations & Product Development	2.8yrs	pas de données	pas de données
Tim Varacek	Senior VP of Commercial & Business Operations	less than a year	pas de données	pas de données
Sai Iyer	Senior Vice President of Medical Affairs & Research	less than a year	pas de données	pas de données

2.3yrs

Durée moyenne de l'emploi

51yo

Âge moyen

Gestion expérimentée: L'équipe de direction de ICU est considérée comme expérimentée (ancienneté moyenne 2.3 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Eric Schlorff	CEO, President & Executive Director	5.3yrs	US$637.96k	1.12% $ 100.2k
Glenn Chertow	Member of Medical Advisory Board	no data	pas de données	pas de données
Ravindra Mehta	Member of Medical Advisory Board	no data	pas de données	pas de données
Kenneth Van Heel	Independent Director	3.8yrs	US$88.16k	0.055% $ 4.9k
Richard Barnett	Independent Chairman	3.8yrs	US$126.16k	0.079% $ 7.1k
Allan Collins	Independent Director	3.8yrs	US$80.16k	0.050% $ 4.5k
David Askenazi	Member of Scientific Advisory Board	less than a year	pas de données	pas de données
Ayse Akcan-Arikan	Member of Scientific Advisory Board	less than a year	pas de données	pas de données
Sean Bagshaw	Member of Scientific Advisory Board	less than a year	pas de données	pas de données
Rajit Basu	Member of Scientific Advisory Board	less than a year	pas de données	pas de données
Andriy Batchinsky	Member of Scientific Advisory Board	less than a year	pas de données	pas de données
John Neuman	Director	less than a year	pas de données	pas de données

0.9yrs

Durée moyenne de l'emploi

60yo

Âge moyen

Conseil d'administration expérimenté: Le conseil d'administration de la ICU n'est pas considéré comme expérimenté ( 0.9 années d'ancienneté moyenne), ce qui suggère un nouveau conseil d'administration.

SeaStar Medical Holding Gestion

Gestion contrôle des critères 3/4

Informations clés

Mises à jour récentes de la gestion

High number of new and inexperienced directors

SeaStar Medical Holding Corporation Announces Board Changes

SeaStar Medical Holding Corporation Approves Class II Director Appointments

SeaStar Medical Holding Corporation, Annual General Meeting, Jun 04, 2024

SeaStar Medical Holding Corporation Announces Chief Financial Officer Changes

SeaStar Medical Forms Scientific Advisory Board of Pediatric and Adult Clinical Experts

Recent updates

FDA Grants Breakthrough Device Designation for Seastar Medical’S Selective Cytopheretic Device for Adults Undergoing Chronic Dialysis

SeaStar Medical Holding Corporation Announces Record Monthly Enrollment Achieve in It's Pivotal Adult AKI Trial

Seastar Medical Holding Corporation Enters into Confidential Settlement Agreement and Release with Nuwellis

Seastar Medical Holding Corporation Announces Enrollment in Its Adult Acute Kidney Injury Pivotal Trial Has Exceeded the Halfway Point Toward an Interim Analysis

SeaStar Medical Holding Corporation has filed a Follow-on Equity Offering in the amount of $25 million.

Levi & Korsinsky, LLP Notifies Investors in Seastar Medical Holding Corporation of A Class Action Securities Lawsuit

SeaStar Medical Holding Corporation Announces First Pediatric Patient Treated in A Commercial Setting with FDA-Approved QUELIMMUNE Therapeutic Device

SeaStar Medical Holding Corporation has completed a Follow-on Equity Offering in the amount of $10.000007 million.

SeaStar Medical Holding Corporation has filed a Follow-on Equity Offering in the amount of $10.000007 million.

SeaStar Medical Holding Corporation has filed a Follow-on Equity Offering in the amount of $10.000007 million.

The Schall Law Firm Reminds Class Action Lawsuit Against SeaStar Medical Holding Corporation

SeaStar Medical Holding Provides Notice to the Nasdaq Stock Market Regarding its Possible Violation of Nasdaq Listing Rule 5635(d)(2)

SeaStar Medical Holding Provides Notice to the Nasdaq Stock Market Regarding its Possible Violation of Nasdaq Listing Rule 5635(d)(2)

SeaStar Medical Holding Corporation Finalizes FDA Labeling Requirement for QUELIMMUNE, Paving the Way for First Commercial Sales as Humanitarian Use Device

High number of new and inexperienced directors

SeaStar Medical Holding Announces Compliance Update with Nasdaq Listing Rule 5550(b)(2) and Nasdaq Listing Rule 5550(a)(2)

SeaStar Medical Holding Corporation Announces Board Changes

SeaStar Medical Holding Corporation Approves Class II Director Appointments

SeaStar Medical Holding Corporation, Annual General Meeting, Jun 04, 2024

SeaStar Medical Announces $3.6 Million NIH Grant Award to Study the Selective Cytopheretic Device in Adult Patients with Severe Chronic Heart Failure

SeaStar Medical Announces $3.6 Million NIH Grant Award to Study the Selective Cytopheretic Device in Adult Patients with Severe Chronic Heart Failure

SeaStar Medical Holding Corporation announced delayed annual 10-K filing

Seastar Medical Provides Updates on Enrollment of Adult Pivotal Clinical Study and Commercial Launch of Quelimmune, FDA-Approved in Pediatric Patients

FDA Grants Humanitarian Device Exemption Approval to Seastar Medical’S Selective Cytopheretic Device for Pediatric Acute Kidney Injury

SeaStar Medical Holding Receives Notification from the Nasdaq Listing Qualifications Department Regarding the Company Regains Compliance with the Market Value Rule

SeaStar Medical Holding Corporation has filed a Follow-on Equity Offering in the amount of $9 million.

SeaStar Medical Holding Corporation has filed a Follow-on Equity Offering in the amount of $9 million.

SeaStar Medical Holding Corporation has filed a Follow-on Equity Offering in the amount of $9 million.

SeaStar Medical Holding Corporation Announces Chief Financial Officer Changes

SeaStar Medical Holding Receives Non-Compliance Notice from Nasdaq

SeaStar Medical Holding Corporation Updates Subject Enrollment in its Pivotal Trial with the Selective Cytopheretic Device in Adults with Acute Kidney Injury

SeaStar Medical Holding Corporation Updates Subject Enrollment in its Pivotal Trial with the Selective Cytopheretic Device in Adults with Acute Kidney Injury

SeaStar Medical Holding Receives Notification from the Nasdaq Listing Qualifications Department of the Nasdaq Stock Market

SeaStar Medical Forms Scientific Advisory Board of Pediatric and Adult Clinical Experts

New major risk - Shareholder dilution

U.S. Food and Drug Administration Issues Approvable Letter for SeaStar Medical Holding Corporation's Selective Cytopheretic Device for Pediatric Patients

FDA Grants SeaStar Medical’s Selective Cytopheretic Device Breakthrough Device Designation for Hepatorenal Syndrome

SeaStar Medical Holding Corporation Announces Publication of Case Series of Three Critically Ill Children with Acute Kidney Injury Safely Treated with it's Selective Cytopheretic Device

SeaStar Medical Holding Corporation Enrolls First Patient in NEUTRALIZE-AKI Pivotal Clinical Trial with the Selective Cytopheretic Device in Adults with Acute Kidney Injury

Seastar Medical Holding Receives Nasdaq Staff Deficiency Letter Regarding Non-Compliance with Market Value of Listed Securities Requirements

SeaStar Medical Holding Corporation, Annual General Meeting, Jun 28, 2023

SeaStar Medical Holding Corporation Provides Regulatory Update Related to HDE Application for Pediatric Selective Cytopheretic Device

SeaStar Medical Announces Details of the Selective Cytopheretic Device Pivotal Study in Critically ill Adults with Acute Kidney Injury

Seastar Medical Receives FDA Approval to Begin Study with Selective Cytopheretic Device to Reduce Hyperinflammation in Adults with Acute Kidney Injury

SeaStar Medical Holding Corporation Submits Investigational Device Exemption Application to FDA to Study a Novel Therapy to Reduce Hyperinflammation in Adult Acute Kidney Injury Patients

High number of new directors

Seastar Medical Appoints Rick Barnett as Chairman of the Board of Directors

No independent directors

SeaStar Medical Announces Positive Interim Safety Findings from Ongoing Study Evaluating the Selective Cytopheretic Device (SCD) in Children

Analyse de la rémunération des PDG

PDG

Titularisation

Compensation

Équipe de direction

Durée moyenne de l'emploi

Âge moyen

Membres du conseil d'administration

Durée moyenne de l'emploi

Âge moyen